An article about a biotech company’s announcement of an AI-designed, preclinical small-molecule candidate aimed at lowering Lp(a) to address cardiovascular risk; it previews the science-driven development approach and program context.
Key Takeaways
- Insilico nominated ISM0900 as a preclinical candidate for oral Lp(a) inhibition
- Preclinical data showed ISM0900 reduced Lp(a) by 83.9% and reached peak effect by Day 4
- Insilico reports nominating 33 PCCs since 2021, with 13 receiving IND approval or clearance